RxDoctor Payments Data

Jennifer Gee

Nurse Practitioner · Palm Bay, FLNPI 1205239944

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 159 payments — averaging $23.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$692
  • AstraZeneca$545
  • AbbVie$312
  • Regeneron Healthcare Solutions, Inc.$266
  • Abbott$250
  • Johnson & Johnson$245
  • plus $1K from 30 others

What the payments were for

  • Food & beverage$3,73899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,758 in reported general payments places this provider in the 90th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$39,432
Medicare patients
173
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide46$58,163
JardianceEmpagliflozin50$39,043
EliquisApixaban30$38,611
CreonLipase/Protease/Amylase13$32,673
FarxigaDapagliflozin Propanediol31$23,203
TradjentaLinagliptin15$15,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,056
MounjaroTirzepatide12$14,025
Humalog Kwikpen U-100Insulin Lispro20$4,013
Levothyroxine Sodium200$3,792
Atorvastatin Calcium224$3,694
SymbicortBudesonide/Formoterol Fumarate14$3,289
Epinephrine11$3,280
Metoprolol Succinate126$3,084
Wixela InhubFluticasone Propion/Salmeterol14$2,761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$692$58,16346 claims
Boehringer IngelheimJardiance, Tradjenta$50$54,12365 claims
PfizerEliquis$124$38,61130 claims
AbbVieCreon, Synthroid$312$33,45527 claims
AstraZenecaFarxiga, Symbicort$545$26,49345 claims
GSKTrelegy Ellipta$214$15,05620 claims
Lilly USA, LLCMounjaro$79$14,02512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Palm Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →